Format
Sort by

Send to

Choose Destination

Search results

Items: 3

1.

Targeted Therapy-based Combination Treatment in Rhabdomyosarcoma.

van Erp AEM, Versleijen-Jonkers YMH, van der Graaf WTA, Fleuren EDG.

Mol Cancer Ther. 2018 Jul;17(7):1365-1380. doi: 10.1158/1535-7163.MCT-17-1131. Review.

PMID:
29967215
2.

Targeting Anaplastic Lymphoma Kinase (ALK) in Rhabdomyosarcoma (RMS) with the Second-Generation ALK Inhibitor Ceritinib.

van Erp AEM, Hillebrandt-Roeffen MHS, van Houdt L, Fleuren EDG, van der Graaf WTA, Versleijen-Jonkers YMH.

Target Oncol. 2017 Dec;12(6):815-826. doi: 10.1007/s11523-017-0528-z.

3.

Expression and clinical association of programmed cell death-1, programmed death-ligand-1 and CD8+ lymphocytes in primary sarcomas is subtype dependent.

van Erp AEM, Versleijen-Jonkers YMH, Hillebrandt-Roeffen MHS, van Houdt L, Gorris MAJ, van Dam LS, Mentzel T, Weidema ME, Savci-Heijink CD, Desar IME, Merks HHM, van Noesel MM, Shipley J, van der Graaf WTA, Flucke UE, Meyer-Wentrup FAG.

Oncotarget. 2017 Jul 7;8(41):71371-71384. doi: 10.18632/oncotarget.19071. eCollection 2017 Sep 19.

Supplemental Content

Loading ...
Support Center